Table 2.

Oncologic findings and clinical outcomesa

Findings and OutcomesLCDD (n = 12)LHCDD (n = 5)HCDD (n = 6)Pure MIDD (n = 23)LCDD & MCN (n = 11)P Value
aResults are given as no. (%) or mean ± SEM. BM, bone marrow; UPEP, urine protein electrophoresis; SPEP, serum protein electrophoresis; MCN, myeloma cast nephropathy; MGUS, monoclonal gammopathy of unknown significance; ESRD, end-stage renal disease; nl, normal.
bDefined in Materials and Methods section.
cLCDD versus LHCDD.
dPure MIDD versus LCDD & MCN.
eAfter renal biopsy diagnosis.
fAt any time during clinical course.
Known M spike prior to bx2 (17%)4 (80%)1 (17%)7 (30%)4 (36%)NS
(+) SPEPe3 (25%)4 (80%)4 (67%)11 (48%)3 (27%)0.04c
(+) UPEPe5 (42%)4 (80%)3 (50%)12 (52%)7 (64%)NS
(-) UPEP AND (-) SPEPe2 (17%)0 (0%)1 (17%)3 (13%)1 (9%)NS
Serum immunofixationf1κ, 41gGκ, 5 nl 1 decr γ and 1 incr α2 IgGκ, 1 IgGλ 2 unknown1 IgGκ, 3 low γ 1 IgAκ and 1 IgMλ1IgGκ, 1κ, 5 nl, 2 γ spike, 1 decr γ 1 unknown
Hypogammaglobulinemia5 (42%)0 (0%)2 (34%)7 (30%)5 (45%)NS
(+) BM biopsy ≥ 15% plasma cells6 (50%)2 (40%)1 (17%)8 (35%)8 (73%)NS
(+) Skeletal survey2 (17%)0 (0%)1 (17%)3 (13%)1 (9%)NS
Corrected Ca2+ > 10.5 mg/dl0 (0%)1 (20%)0 (0%)1 (4.3%)3 (27%)NS
Clinical diagnosisb multiple myeloma7 (58%)1 (20%)1 (17%)9 (39%)10 (91%)0.025d
MGUSb2 (17%)3 (60%)4 (66%)9 (39%)0 (0%)
isolated HCDD0 (0%)0 (0%)1 (17%)1 (4%)0 (0%)
insufficient data3 (25%)1 (20%)0 (0%)4 (17%)1 (9%)
Mean follow-up time (mo)33.2 ± 9.59.1 ± 5.114.8 ± 6.622.6 ± 5.614.7 ± 3.4
range (mo)(7-99)(1-27)(2-42)(1-99)(0.2-36)
Renal outcome0.057d
ESRD/dialysis at presentation3 (25%)2 (40%)3 (50%)8 (35%)9 (82%)0.053d
stable/improvedb5 (42%)2 (40%)3 (50%)10 (43%)1 (9%)
worsening renal functionb1 (8%)1 (20%)0 (0%)2 (9%)0 (0%)
progression to ESRD/dialysisb3 (25%)0 (0%)0 (0%)3 (13%)1 (9%)
ESRD/dialysis at study end6 (50%)2 (40%)3 (50%)11 (48%)10 (91%)0.063d
Mean time to ESRD (mo)27832240.0196d
Mean time to death (mo)69134254220.05d/0.01c
Patient deaths6 (50%)3 (60%)1 (17%)10 (43%)6 (55%)NS